Market closedNon-fractional
Prelude Therapeutics/PRLD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Ticker
PRLD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Wilmington, United States
Employees
128
Website
preludetx.com
PRLD Metrics
BasicAdvanced
$329M
Market cap
-
P/E ratio
-$1.87
EPS
1.54
Beta
-
Dividend rate
Price and volume
Market cap
$329M
Beta
1.54
Financial strength
Current ratio
11.64
Quick ratio
11.445
Long term debt to equity
7.332
Total debt to equity
8.371
Management effectiveness
Return on assets (TTM)
-38.59%
Return on equity (TTM)
-65.04%
Valuation
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-3.612
Growth
Earnings per share change (TTM)
-21.81%
3-year earnings per share growth (CAGR)
-14.10%
What the Analysts think about PRLD
Analyst Ratings
Majority rating from 4 analysts.
PRLD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$31M
-4.85%
Profit margin
0.00%
NaN%
PRLD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.45
-$0.46
-$0.42
-
Expected
-$0.63
-$0.58
-$0.49
-$0.49
-$0.42
Surprise
-14.74%
-22.72%
-6.12%
-13.40%
-
PRLD News
AllArticlesVideos
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
GlobeNewsWire·3 weeks ago
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
GlobeNewsWire·2 months ago
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prelude Therapeutics stock?
Prelude Therapeutics (PRLD) has a market cap of $329M as of July 27, 2024.
What is the P/E ratio for Prelude Therapeutics stock?
The price to earnings (P/E) ratio for Prelude Therapeutics (PRLD) stock is 0 as of July 27, 2024.
Does Prelude Therapeutics stock pay dividends?
No, Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Prelude Therapeutics dividend payment date?
Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Prelude Therapeutics?
Prelude Therapeutics (PRLD) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Prelude Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.